Photocure to present at Nordic-American Life Science Conference in New York

Oslo, Norway, 29 November 2018: Photocure ASA (OSE: PHO) is pleased to announce that Photocure will be presenting at the Nordic-American Life Science Conference in New York today. The presentation will be held by Daniel Schneider, President and CEO of Photocure ASA.

The presentation will be available on Photocure’s website (www.photocure.com) in the investor relations section following the presentation.

About Hexvix®/Cysview®  
Hexvix®/Cysview® is a drug that is taken up selectively by cancer cells in the bladder making them glow bright pink during Blue Light Cystoscopy (BLC™). BLC™ with Hexvix® /Cysview® improves the detection of tumors and leads to more complete resection, less residual tumors and better management decisions.

Cysview® is the tradename in the US and Canada, Hexvix® is the tradename in all other markets. Photocure is commercializing Hexvix®/Cysview® directly in the US and the Nordic region and has strategic partnerships for the commercialization of Hexvix®/Cysview® in Europe, Canada, Australia and New Zealand. Please refer to https://www.photocure.com/Partnering-with-Photocure/Our-partners for further information on our commercial partners.

About Photocure ASA
Photocure, The Bladder Cancer Company, delivers transformative solutions to improve the lives of bladder cancer patients. Our unique technology, making cancer cells glow bright pink, has led to better health outcomes for patients worldwide. Photocure is headquartered in Oslo, Norway and listed on the Oslo Stock Exchange (OSE: PHO). For more information, please visit us at www.photocure.com, www.hexvix.com, www.cysview.com.

All trademarks mentioned in this release are protected by law and are registered trademarks of Photocure ASA

For further information, please contact:

Photocure
President and CEO, Daniel Schneider
Tel: +1 5084108044
E-mail: ds@photocure.com

CFO Erik Dahl
Tel: +47 450 55 000
E-mail: ed@photocure.no